This is an aggregated industry headline. Read the full story at Drug Channels →
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders. Click here to see the original post from March 2026. By Adam J. Fein, Ph.D.Next week, the Drug Channels Institute (DCI) wi
By Drug Channels
· Jun 8, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is strugglin…
The WeekFierceBiotech ↗
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease …
The WeekBriefing
Nuvalent’s Jideytro won FDA approval for adults with locally advanced or metastatic ROS1-positive NSCLC after …